Abstract: The present invention provides gene sets, the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
Type:
Grant
Filed:
January 31, 2006
Date of Patent:
May 25, 2010
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Type:
Grant
Filed:
January 11, 2007
Date of Patent:
April 13, 2010
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett, Drew Watson, Soonmyung Paik
Abstract: The present invention provides a method of screening for markers useful in predicting the efficacy of a specified cancer that includes: (a) constructing a tissue microarray from a tissue bank comprising multiple tissue samples that are annotated with clinical follow up data; (b) labeling polynucleic acid probes specific for oncogenes or cancer associated genes known to be potential amplicons; (c) performing fluorescent in situ hybridization analysis on the tissue microarray; and (d) correlating the result of the fluorescent in situ hybridization with the clinical follow up data. The present disclosure also provides methods of treating breast cancer that include screening a breast cancer patient for amplification of one or more of the genes disclosed herein, and treating a patient having amplification of one or more of these genes with a therapeutically effective amount of a compound that interferes with HER2 signaling.
Abstract: The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measure as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotherapy.
Type:
Grant
Filed:
November 4, 2005
Date of Patent:
November 24, 2009
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
Abstract: A method of predicting clinical outcome in a subject diagnosed with cancer and treated with chemotherapy comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample comprising cancer cells obtained from the subject.
Type:
Application
Filed:
March 14, 2008
Publication date:
October 15, 2009
Applicants:
GENOMIC HEALTH, INC., NSABP FOUNDATION, INC.
Inventors:
Wayne Cowens, Joffre Baker, Kim Langone, Drew Watson, James Hackett, Soonmyung Paik
Abstract: The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.
Type:
Grant
Filed:
June 30, 2004
Date of Patent:
April 28, 2009
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
Abstract: The present invention provides a method of screening for markers useful in predicting the efficacy of the treatment of a specified cancer that includes: (a) constructing a tissue microarray from a tissue bank comprising multiple tissue samples that are annotated with clinical follow-up data; (b) labeling polynucleic acid probes specific for oncogenes or cancer-associated genes known to be potential amplicons; (c) performing fluorescent in situ hybridization analysis on the tissue microarray; and (d) correlating the result of the fluorescent in situ hybridization with the clinical follow-up data. In addition, the present invention provides a method of treating breast cancer that includes measuring the expression levels or amplification of HTPAP in a patient having breast cancer and then providing a patient having increased levels of HTPAP expression or HTPAP amplification with therapeutic quantities of at least one compound that interferes with the phosphatidic acid phosphatase activity of HTPAP.
Abstract: The present invention provides novel methods for analyzing gene expression levels from fresh or aged (more than one year old) formalin-fixed, paraffin-embedded tissue (“FFPET”) samples that comprise pre-hybridizing a labeled nucleic acid sample prepared from the formalin-fixed, paraffin-embedded tissue sample with a first microarray, hybridizing the unbound labeled nucleic acid sample with a second microarray, and detecting the labeled nucleic acid sample bound to the second microarray. The pre-hybridization step results in an increase in the specific gene signals in subsequent hybridizations with high density gene expression arrays. The first microarray used for the pre-hybridization step can be either a new or used microarray.
Type:
Application
Filed:
April 30, 2007
Publication date:
November 1, 2007
Applicant:
NSABP Foundation, Inc.
Inventors:
Soonmyung Paik, Katherine Pogue-Geile, Chungyeul Kim
Abstract: The present invention provides a method of screening for markers useful in predicting the efficacy of a specified cancer that includes: (a) constructing a tissue microarray from a tissue bank comprising multiple tissue samples that are annotated with clinical follow up data; (b) labeling polynucleic acid probes specific for oncogenes or cancer associated genes known to be potential amplicons; (c) performing fluorescent in situ hybridization analysis on the tissue microarray; and (d) correlating the result of the fluorescent in situ hybridization with the clinical follow up data. In addition, the present invention provides a method of treating breast cancer that includes measuring the expression levels or amplification of HTPAP in a patient having breast cancer and then providing a patient having increased levels of HTPAP expression or HTPAP amplification with therapeutic quantities of at least one compound that interferes with the phosphatidic acid phosphatase activity of HTPAP.
Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
Type:
Grant
Filed:
June 17, 2004
Date of Patent:
June 6, 2006
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak